Evotec Nominates First Preclinical Dermatology Candidate with Almirall, Accelerating Development
Summary
Evotec SE announced the nomination of its first preclinical development candidate (PDC) in its dermatology collaboration with Almirall S.A. This significant milestone was achieved within just two years, notably faster than typical industry timelines, underscoring the efficiency of Evotec's integrated, AI/ML-driven R&D platforms. The program aims to develop novel treatments for immune-mediated inflammatory skin diseases. This advancement is a positive catalyst for Evotec, as the existing collaboration agreement includes potential success-based milestones of up to €230 million per program and high single-digit royalties on net sales, enhancing the company's long-term pipeline value. Investors will watch for further progress towards IND submission and clinical trials.
At the time of this announcement, EVO was trading at $3.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.31 to $4.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.